Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

Truist lowered the firm’s price target on Hims & Hers to $37 from $48 and keeps a Hold rating on the shares. The firm’s intra-quarter Truist Card Data suggests that the company’s GLP-1 related ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...

Berkshire Hathaway invests in UnitedHealth; FTC investigates Hims & Hers for advertising practices; U.S. health department ...